LLY241206C940000
- 0.08
- +0.05+166.67%
Eli Lilly and Co Newsroom
Express News | Eli Lilly and Co's weight loss drug Zepbound surpassed Novo Nordisk A/S's Wegovy in its first comparative trial.
10 Health Care Stocks Whale Activity In Today's Session
Stock Of The Day: Where Will The Eli Lilly Rally End?
eli lilly and co (LLY.US) claims that its Zepbound weight loss effect is superior to its competitor Wegovy.
Eli Lilly and Company (LLY.US) stated on Wednesday that its Zepbound weight loss drug was more effective than competitor Novo Nordisk (NVO.US)'s Wegovy in a study, causing Eli Lilly's stock price to rise over 3%. Eli Lilly pointed out that in obese adults without diabetes, Zepbound resulted in an average weight loss of 20.2% at 72 weeks, while Wegovy led to an average weight loss of 13.7%. Zepbound is a dual GIP and GLP-1 receptor agonist, while Wegovy is a single GLP-1 receptor agonist, with GIP and GLP being blood sugar-lowering
Eli Lilly Says Zepbound's Weight-loss Results Beat Those of Rival Wegovy
Express News | Head-to-head studies show that eli lilly and co's telmisartan has a better weight loss effect than semaglutide.
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Novo Nordisk Shares Dipped on Eli Lilly's Zepbound Results -- Market Talk
Eli Lilly and Co announced that Zepbound has better weight loss effects compared to novo-nordisk a/s Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight-loss drug Zepbound had a greater weight-loss effect than the similar drug Wegovy from competitor novo-nordisk a/s; eli lilly and co is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
The results are even better than Wegovy! Eli Lilly and Co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, jumping 2.5% in premarket.
Participants using novo-nordisk a/s's Wegovy only lost 14%. This result provides eli lilly and co an opportunity to catch up, especially with the obesity drug market expected to reach 130 billion dollars by the end of this decade.
U.S. Stock Outlook | Salesforce, Micron, and other technology stocks' earnings reports boost confidence! The three major futures indices are collectively rising in pre-market trading.
Okta surged 14% in the premarket! Q3 performance exceeded expectations, and AI applications continued to explode; Apple “stood by” Amazon and said it was considering pre-training large models using its AI chips.
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Express News | Rondo Therapeutics Announces Collaboration With Lilly to Develop Novel Cd28 Bispecific Antibodies for Solid Tumors
Eli Lilly and Co (LLY.US) outperformed novo-nordisk a/s (NVO.US) in comparative trials, with Zepbound showing superiority over Wegovy.
Eli Lilly and Co (LLY.US) stated that its weight loss drug Zepbound performed better than the competitor Novo-Nordisk A/S (NVO.US) in the first head-to-head trial.
Eli Lilly and Company's (NYSE:LLY) Intrinsic Value Is Potentially 64% Above Its Share Price
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study
Express News | Eli Lilly Shares up 1.3% Premarket After Co's Weight-Loss Drug Tops Rival Wegovy in Head-to-Head Study
Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
Express News | Lilly: In Phase 3B Trial, Participants Using Zepbound Lost 50.3 Lbs. (22.8 Kg) and Participants on Wegovy Lost 33.1 Lbs. (15.0 Kg)
Express News | Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%